Tranexamic Acid NDC 23155-166

NDC codes

FDA NDC Directory

Product NDC (as listed)23155-166Labeler and product segments. Claims need a package NDC.

Product NDC at billing width23155-0166Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
23155-166-41	23155016641	10 VIAL, GLASS in 1 CARTON (23155-166-41) / 10 mL in 1 VIAL, GLASS (23155-166-31)Marketed from Aug 13, 2014

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Tranexamic Acid
Generic name (nonproprietary): tranexamic acid
Active ingredients: Tranexamic acid — 1 g/10mL
Dosage form: Injection, Solution
Route: Intravenous
Labeler: Heritage Pharmaceuticals Labs Inc. d/b/a Avet Pharmaceuticals Labs Inc.
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 203521
Marketing start: Aug 13, 2014
Listing expires: Dec 31, 2027
Other FDA classes: Decreased Fibrinolysis (Physiologic effect)
Identifiers: Product ID 23155-166_0af5a738-6084-4cec-a0d9-0aff3f86d8f7SPL ID 0af5a738-6084-4cec-a0d9-0aff3f86d8f7SPL set ID 28ccedba-99cd-49f3-a782-798df5258524RxCUI 238720UNII 6T84R30KC1
Pharmacologic class: Antifibrinolytic Agent

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No drug-specific HCPCS code in Med-Code's directory for this product. The directory is curated and not complete — check the current CMS HCPCS file before billing.

Administration

Drug administration (CPT 96360–96549)

When a clinician administers the drug, the administration is reported separately. Codes in this range cover hydration, therapeutic injections and infusions, and chemotherapy or other complex drug administration. The right code depends on route, duration and drug type, and self-administered drugs are not billed this way.

How CPT relates to drug billing

NDC on a medical claim

N423155016641 followed by a unit qualifier and the quantity

Package 23155-0166-41. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective May 27, 2026. This label includes a boxed warning.

Indications (excerpt from the label)

Tranexamic acid injection, USP is indicated in patients with hemophilia for short-term use (2 to 8 days) to reduce or prevent hemorrhage and reduce the need for replacement therapy during and following tooth extraction. Tranexamic acid injection is an antifibrinolytic indicated in patients with hemophilia for short-term use (2 to 8 days) to reduce or prevent hemorrhage and reduce the need for replacement therapy during and following tooth extraction.

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 203521

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 203521
Product	Strength	Form · route	Labeler	Product NDC
tranexamic acid	Tranexamic acid 100 mg/mL	Injection, SolutionIntravenous	Avenacy, Inc.	83634-401
Tranexamic Acid	Tranexamic acid 100 mg/mL	InjectionIntravenous	Northstar Rx LLC	72603-387
Tranexamic Acid	Tranexamic acid 1 g/10mL	Injection, SolutionIntravenous	Emcure Pharmaceuticals Limited	14593-318
Tranexamic Acid	Tranexamic acid 1 g/10mL	Injection, SolutionIntravenous	Heritage Pharmaceuticals Labs Inc. d/b/a Avet Pharmaceuticals Labs Inc.	23155-524